Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror | BioSpace
TEVA stock as EU cites antitrust concerns over multiple sclerosis therapy (NYSE:TEVA) | Seeking Alpha
Virtual MS Medical Forum | Neurologybytes Events
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Business Wire
Teva Long-Term Prospects Bright, Despite Headwinds - TipRanks.com
Teva Pharmaceutical's Sales Slump 18% - WSJ
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
NICE reconsiders and agrees to back Roche's Ocrevus in relapsing multiple sclerosis—with strings attached | Fierce Pharma
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | BioSpace
Biogen sues Teva over MS generic
Skinny labels' at forefront of possible Supreme Court biopharma cases | BioWorld
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
EU launches antitrust probe against Teva - www.israelhayom.com
Teva: It's Never Too Late to Sell | Barron's
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Teva reports new Copaxone data in breastfeeding mothers with relapsing multiple sclerosis | Seeking Alpha
EU Probes Teva For Blocking Rivals To Multiple Sclerosis Drug
Teva defends Copaxone from Dutch patent challenge - PMLiVE
High-Court-Sides-Teva-Patent
Teva tumbles as sales and earnings underwhelm
